Northrop Grumman (NOC) At $327.82 Forms Top; Depomed (DEPO) Shorts Up By 0.26%

Northrop Grumman Corporation (NYSE:NOC) Logo

Depomed Inc (NASDAQ:DEPO) had an increase of 0.26% in short interest. DEPO’s SI was 10.15M shares in June as released by FINRA. Its up 0.26% from 10.12 million shares previously. With 846,900 avg volume, 12 days are for Depomed Inc (NASDAQ:DEPO)’s short sellers to cover DEPO’s short positions. The SI to Depomed Inc’s float is 21.84%. The stock increased 0.72% or $0.05 during the last trading session, reaching $6.98. About 839,987 shares traded. Depomed, Inc. (NASDAQ:DEPO) has declined 38.98% since June 14, 2017 and is downtrending. It has underperformed by 51.55% the S&P500. Some Historical DEPO News: ; 10/05/2018 – DepoMed 1Q Rev $128.4M; 14/05/2018 – DEPOMED HOLDER STARBOARD VALUE REPORTS REDUCED STAKE OF 6.1%; 21/05/2018 – Depomed Forms Golden Cross: Technicals; 10/05/2018 – DepoMed 1Q EPS 48c; 02/04/2018 – DepoMed Stan Bukofzer Appointed Chief Medical and Scientific Office; 02/04/2018 – DepoMed: Vetticaden to Remain With Company Through the End of April to Ensure a Smooth Transition; 11/05/2018 – DEPO HLDRS OK PROPOSAL ON BOARD WRITING REPUTATION-RISKS REPORT; 21/05/2018 – Depomed Presenting at UBS Conference Tomorrow; 17/04/2018 – Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications; 14/05/2018 – STARBOARD VALUE LP – HAD PREVIOSULY REPORTED 7.5 PCT STAKE IN DEPOMED INC AS OF APRIL 3, 2018 – SEC FILING

Northrop Grumman Corporation (NOC) formed multiple top with $357.32 target or 9.00% above today’s $327.82 share price. Northrop Grumman Corporation (NOC) has $57.17B valuation. The stock decreased 0.46% or $1.53 during the last trading session, reaching $327.82. About 928,888 shares traded. Northrop Grumman Corporation (NYSE:NOC) has risen 29.40% since June 14, 2017 and is uptrending. It has outperformed by 16.83% the S&P500. Some Historical NOC News: ; 25/04/2018 – Northrop Grumman Had Seen 2018 EPS $15.00-$15.25; 25/04/2018 – NOC SEES FY EPS $15.40 TO $15.65, SAW $15 TO $15.25; 23/05/2018 – Northrop Grumman at AllianceBernstein Conference May 31; 28/03/2018 – NORTHROP SAYS POLAND SIGNS LOI FOR IAMD IBCS; 09/04/2018 – Two independent investigations point to the Northrop’s payload adapter as the cause of the satellite’s loss, the report said; 28/03/2018 – Poland Signs Agreement to Purchase Northrop Grumman’s Integrated Air and Missile Defense Battle Command System; 25/04/2018 – Northrop Grumman Still Sees 2018 Sales About $27B; 25/04/2018 – Northrop Grumman Releases First Quarter 2018 Financial Results; 28/03/2018 – Northrop Grumman: Poland Agrees to Buy Integrated Air and Missile Defense Battle Command System; 30/03/2018 – Northrop Grumman: Victor H. Fazio to Retire From Board

More important recent Depomed, Inc. (NASDAQ:DEPO) news were published by: which released: “The Jury’s Still Out On Depomed” on May 21, 2018, also published article titled: “Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)”, published: “Depomed Announces the Appointment of Phillip B. Donenberg as Chief Financial Officer” on June 05, 2018. More interesting news about Depomed, Inc. (NASDAQ:DEPO) was released by: and their article: “FDA OKs first non-opioid treatment for opioid withdrawal” with publication date: May 16, 2018.

Investors sentiment increased to 1.36 in Q1 2018. Its up 0.43, from 0.93 in 2017Q4. It is positive, as 15 investors sold Depomed, Inc. shares while 40 reduced holdings. 29 funds opened positions while 46 raised stakes. 60.75 million shares or 8.72% more from 55.87 million shares in 2017Q4 were reported. Bnp Paribas Arbitrage holds 0% in Depomed, Inc. (NASDAQ:DEPO) or 20,295 shares. Massachusetts Fincl Service Ma holds 0% or 166,224 shares. Schwab Charles Mgmt reported 399,324 shares. The Kansas-based Creative Planning has invested 0% in Depomed, Inc. (NASDAQ:DEPO). Parkside National Bank Trust, Missouri-based fund reported 78 shares. Envestnet Asset holds 0% of its portfolio in Depomed, Inc. (NASDAQ:DEPO) for 61 shares. Panagora Asset Management holds 0% or 11,760 shares in its portfolio. Us Fincl Bank De reported 0% in Depomed, Inc. (NASDAQ:DEPO). Alabama-based Regions Fincl has invested 0% in Depomed, Inc. (NASDAQ:DEPO). Bank & Trust Of America De accumulated 52,071 shares. Jpmorgan Chase & has 837,138 shares. Glenmede Comm Na has invested 0% in Depomed, Inc. (NASDAQ:DEPO). Alberta – Canada-based Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Mngmt Corporation has invested 0% in Depomed, Inc. (NASDAQ:DEPO). 128,313 are owned by New York State Teachers Retirement Sys. 36,874 were accumulated by International Grp Inc Inc.

Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. The company has market cap of $443.84 million. It offers Gralise , an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. It currently has negative earnings. The firm also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults.

Since March 7, 2018, it had 0 insider buys, and 2 sales for $438,610 activity. $299,515 worth of Depomed, Inc. (NASDAQ:DEPO) was sold by Gosling Matthew M on Wednesday, March 7.

Among 14 analysts covering Depomed Inc (NASDAQ:DEPO), 6 have Buy rating, 2 Sell and 6 Hold. Therefore 43% are positive. Depomed Inc had 54 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Depomed, Inc. (NASDAQ:DEPO) earned “Buy” rating by Roth Capital on Wednesday, November 11. RBC Capital Markets maintained the stock with “Sector Perform” rating in Tuesday, February 23 report. The firm has “Buy” rating by WallachBeth Capital given on Wednesday, November 11. The firm has “Neutral” rating given on Tuesday, August 8 by Janney Capital. RBC Capital Markets maintained it with “Hold” rating and $10.0 target in Thursday, September 14 report. The rating was maintained by Mizuho with “Buy” on Friday, March 23. The stock has “Buy” rating by Mizuho on Monday, May 9. Piper Jaffray initiated the shares of DEPO in report on Monday, February 8 with “Overweight” rating. Roth Capital maintained it with “Buy” rating and $33 target in Tuesday, September 1 report. The company was maintained on Thursday, February 25 by Mizuho.

Investors sentiment decreased to 0.88 in 2018 Q1. Its down 0.10, from 0.98 in 2017Q4. It turned negative, as 57 investors sold Northrop Grumman Corporation shares while 306 reduced holdings. 89 funds opened positions while 232 raised stakes. 137.81 million shares or 0.54% more from 137.07 million shares in 2017Q4 were reported. Cobblestone Capital Ltd reported 0.08% stake. Ww Investors accumulated 0.37% or 4.72 million shares. New York-based Stone Ridge Asset Limited Co has invested 0.04% in Northrop Grumman Corporation (NYSE:NOC). 7,038 are owned by Wright Invsts Serv. Ironwood Inv Counsel Limited has 0.09% invested in Northrop Grumman Corporation (NYSE:NOC). Brinker Cap accumulated 24,731 shares or 0.34% of the stock. Bnp Paribas Asset Mgmt Hldg reported 163,416 shares. Oakbrook Investments Ltd Liability Com holds 0.3% of its portfolio in Northrop Grumman Corporation (NYSE:NOC) for 14,062 shares. Parallax Volatility Advisers Lp accumulated 0% or 35 shares. Abner Herrman & Brock Limited Liability has invested 0.6% in Northrop Grumman Corporation (NYSE:NOC). Bb&T Lc, Virginia-based fund reported 7,196 shares. Amica Retiree Med stated it has 812 shares. Gateway Advisers Lc invested 0.09% in Northrop Grumman Corporation (NYSE:NOC). Signature Est Invest Advsrs Limited Com has invested 0.3% of its portfolio in Northrop Grumman Corporation (NYSE:NOC). Estabrook Capital Mngmt stated it has 13,391 shares.

Among 20 analysts covering Northrop Grumman (NYSE:NOC), 13 have Buy rating, 0 Sell and 7 Hold. Therefore 65% are positive. Northrop Grumman had 66 analyst reports since July 30, 2015 according to SRatingsIntel. The stock has “Buy” rating by Drexel Hamilton on Wednesday, October 28. RBC Capital Markets maintained the shares of NOC in report on Thursday, October 26 with “Buy” rating. As per Monday, January 8, the company rating was maintained by Stifel Nicolaus. The firm earned “Buy” rating on Friday, June 2 by RBC Capital Markets. The firm has “Equal-Weight” rating given on Monday, May 2 by Barclays Capital. The stock of Northrop Grumman Corporation (NYSE:NOC) has “Outperform” rating given on Friday, January 29 by RBC Capital Markets. The firm has “Hold” rating given on Tuesday, May 22 by Credit Suisse. RBC Capital Markets maintained Northrop Grumman Corporation (NYSE:NOC) rating on Friday, September 29. RBC Capital Markets has “Buy” rating and $294.0 target. On Wednesday, February 14 the stock rating was upgraded by Jefferies to “Buy”. Citigroup maintained Northrop Grumman Corporation (NYSE:NOC) on Monday, March 12 with “Buy” rating.

Depomed, Inc. (NASDAQ:DEPO) Institutional Positions Chart